GRL-0617 is a drug which is one of the first compounds discovered that acts as a selective small-molecule inhibitor of the
proteaseenzymepapain-like protease (PLpro) found in some human pathogenic viruses, including the
coronavirusSARS-CoV-2. It has been shown to inhibit viral replication in silico[1] and in vitro.[2][3][4][5]
^Shanker AK, Bhanu D, Alluri A, Gupta S (May 2020). "Whole-genome sequence analysis and homology modelling of the main protease and non-structural protein 3 of SARS-CoV-2 reveal an aza-peptide and a lead inhibitor with possible antiviral properties". New Journal of Chemistry. 44 (22): 9202–9212.
doi:
10.1039/D0NJ00974A.
S2CID218938798.